Pediatric anesthesia & critical care

Intraoperative dexmedetomidine and acute kidney injury in paediatric noncardiac surgery: a retrospective propensity score-matched analysis

Br J AnaesthPublished Retrospective cohort study

Main finding · AKI within 7 days after surgeryResult — go to the resultOdds ratio 0.43 95% CI 0.27–0.66

Authors' conclusion

This retrospective analysis of a single-centre paediatric noncardiac surgery cohort suggests that intraoperative dexmedetomidine infusion was associated with a lower incidence of AKI within 7 days after surgery.

Study context

Population
Paediatric patients undergoing noncardiac surgery, January 2019–July 20211,858/4091 received dexmedetomidine after matching
Exposure
Dexmedetomidine vs No dexmedetomidine
Outcome
Acute kidney injury (AKI)
Follow-up
Within 7 days after surgery
Methodological detailspropensity-score matched, single-centre, multivariable logistic and linear regression in matched cohort
  • Propensity-score matched
  • Single-centre
  • Multivariable logistic and linear regression in matched cohort

Main finding

AKI within 7 days after surgery

Odds ratio

0.43

95% CI 0.27–0.66

P < 0.001

By group

Dexmedetomidine vs No dexmedetomidine
OR 0.43 (95% CI 0.27–0.66); P < 0.001

As reported in the abstract

Observational data: associations, not effects.

Secondary outcomes

OutcomeOR (95% CI)P value
Postoperative ICU admission0.35 (0.30–0.42)P < 0.001

Length of hospitalisation · shorter hospitalisation

P < 0.001

In-hospital mortality

Similar between the matched groups

Safety

Intraoperative bradycardia and hypotension

Similar between the matched groups

Original publication

Intraoperative dexmedetomidine and acute kidney injury in paediatric noncardiac surgery: a retrospective propensity score-matched analysis. Br J Anaesth. Published 12 December 2024. doi:10.1016/j.bja.2024.10.016

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.